Статья
Вклад генов Toll-подобных рецепторов в этиопатогенез ишемической болезни сердца
Настоящая работа направлена на обобщение имеющихся в настоящее время публикаций по проблеме вклада полиморфизмов генов рецепторов врожденного иммунитета, в частности Toll-like рецепторов, в патогенез атеросклеротического поражения сосудов сердца. Описаны сигнальные пути TLRs, а также многообразие имеющихся аллельных вариантов кодирующих их генов и взаимосвязь полиморфных вариантов TLRs с различными патологическими состояниями. Показана достоверная связь отдельных аллельных вариантов генов TLRs с развитием и прогрессированием атеросклероза в различных популяциях. Исследования в этой области весьма ограничены и требуют дополнительного изучения.
1. Статинова Е. А. Инфекционные агенты в развитии атеросклероза / Е. А. Статинова, Р. Я. Омельченко, А. О. Аурсалиди // Атеросклероз. – 2013. – № 4. – С. 51–64.
2. Hasan U. A., Trinchieri G., Vlach J. Toll-like receptor signaling stimulates cell cycle entry and progression in fibroblasts // J. Biol. Chem. 2005. Vol. 280, N 21. P. 20620–20627.
3. Chen G. Y., Nuñez G. Review. Sterile inflammation: sensing and reacting to damage // Nat. Rev. Immunol. 2010. Vol. 10, N 12. P. 826–837.
4. Тухватуллин А. И. Toll-подобные рецепторы и их адапторные молекулы / А. И. Тухватуллин, Д. Ю. Логунов, Д. Н. Щербинин // Биохимия. – 2010. – Т. 75, № 9. – С. 1224–1243.
5. Wan Y., Xiao H., Affolter J. et al. Interleukin-1 receptor-associated kinase 2 is critical for lipopolysaccharide-mediated post-transcriptional control // J. Biol. Chem. 2009. Vol. 284, N 16. P. 10367–10375.
6. Basith S., Manavalan B., Lee G. et al. Toll-like receptor modulators: a patent review // Expert. Opin. Ther. Pat. 2011. Vol. 21, N 6. P. 927–944.
7. McGettrick A. F., O’Neill L. A. Localisation and trafficking of Toll-like receptors: an important mode of regulation // Curr. Opin. Immunol. 2010. Vol. 22, N 1. P. 20–27.
8. Barton G. M., Medzhitov R. Toll-like receptor signaling pathways // Science. 2003. Vol. 300. P. 1524–1525.
9. Engel A. L., Holt G. E., Lu H. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system // Expert. Rev. Clin. Pharmacol. 2011. Vol. 4, N 2. P. 275–289.
10. Liu Y., Chen H., Sun Y., Chen F. Antiviral role of Toll-like receptors and cytokines against the new 2009 H1N1 virus infection // Mol. Biol. Rep. 2012. Vol. 39, N 2. P. 1163–1172.
11. Huang L. Y., Dumontelle J. L., Zolodz M. et al. Use of toll-like receptor assays to detect and identify microbial contaminants in biological products // J. Clin. Microbiol. 2009. Vol. 47, N 11. P. 3427–3434.
12. Mashima R., Saeki K., Yoshimura A. et al. FLN29, a novel interferon- and LPS-inducible gene acting as a negative regulator of toll-like receptor signaling // J. Biol. Chem. 2005. Vol. 280, N 50. P. 41289–41297.
13. Jain S., Chodisetti S. B., Agrewala J. N. et al. CD40 signaling synergizes with TLR-2 in the BCR independent activation of resting B cells // PloS ONE. 2011. Vol. 6, N 6. P. e20651.
14. Wang Y., Lehner T. Induction of innate immunity in control of mucosal transmission of HIV // Curr. Opin. HIV AIDS. 2011. Vol. 6, N 5. P. 398–404.
15. Salem M. L., El-Naggar S. A., Cole D. J. Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo // Cell Immunol. 2010. Vol. 261, N 2. P. 134–143.
16. Asprodites N., Zheng L., Geng D. et al. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity // FASEB J. 2008. Vol. 22, N 10. P. 3628–3637.
17. Lin Q., Li M., Fang D. et al. The essential roles of Toll-like receptor signaling pathways in sterile inflammatory diseases // Int. Immunopharm. 2011. Vol. 11, N 10. P. 1422–1432.
18. Crellin N. K., Garcia R. V., Hadisfar O. et al. Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells // J. Immunol. 2005. Vol. 175, N 12. P. 8051–8059.
19. Sutmuller R. P., Morgan M. E., Netea M. G. et al. Toll-like receptors on regulatory T cells: expanding immune regulation // Trends. Immunol. 2006. Vol. 27, N 8. P. 387–393.
20. Jung Y. O., Cho M. L., Lee S.Y. et al. Synergism of toll-like receptor 2 (TLR2), TLR4, and TLR6 ligation on the production of tumor necrosis factor (TNF)-alpha in a spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist-deficient mice // Immunol. Lett. 2009. Vol. 123, N 2. P. 138–143.
21. Lu Q., Darveau R. P., Samaranayake L. P. et al. Differential modulation of human {beta}-defensins expression in human gingival epithelia by Porphyromonas gingivalis lipopolysaccharide with tetra- and penta-acylated lipid A structures // Innate Immun. 2009. Vol. 15, N 6. P. 325–335.
22. Aoki M. P., Carrera-Silva E. A., Cuervo H. et al. Non-immune cells contribute to crosstalk between immune cells and inflammatory mediators in the innate response to Trypanosoma cruzi infection // J. Parasitol. Res. 2012. Vol. 10. P. 13.
23. Arumugam T. V., Okun E., Tang S. et al. Toll-like receptors in ischemia-reperfusion injury // Shock. 2009. Vol. 32, N 1. P. 4–16.
24. Хаитов Р. М., Пащенко М. В., Пинегин Б. В. Роль паттернраспознающих рецепторов во врожденном и адаптивном иммунитете / Р. М. Хаитов, М. В. Пащенко, Б. В. Пинегин // Иммунология. – 2009. – № 1. – С. 66–76.
25. Chao W. Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart // Am. J. Physiol. Heart. Circ. Physiol. 2009. Vol. 296. P. H1–H12.
26. Boyd J. H., Mathur S., Wang Y., Bateman R. M., Walley K. R. Toll-like receptor stimulation in cardiomyocytes decreases contractility and initiates an NF-kappa B dependent inflammatory response // Cardiovasc. Res. 2006. Vol. 72. P. 384–393.
27. Nemoto S., Vallejo J. G., Knuefermann P. at al. Escherichia coli LPS-induced LV dysfunction: role of toll-like receptor-4 in the adult heart // Am. J. Physiol. Heart Circ. Physiol. 2002. Vol. 282. P. H2316–H2323.
28. Knuefermann P., Sakata Y., Baker J. S. at al. Toll-like receptor 2 mediates Staphylococcus aureus-induced myocardial dysfunction and cytokine production in the heart // Circulation. 2004. Vol. 110. P. 3693–3698.
29. Zhu X., Bagchi A., Zhao H. at al. Toll-like receptor 2 activation by bacterial peptidoglycan-associated lipoprotein activates cardiomyocyte inflammation and contractile dysfunction // Crit. Care Med. 2007. Vol. 35, N 3. P. 886–892.
30. Hansson G. K., Libby P., Schonbeck U. et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis // Circ. Res. 2002. Vol. 91. P. 281–291.
31. Ohashi K., Burkart V., Flohe S. et al. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex // J. Immunol. 2000. Vol. 164. P. 558–561.
32. Vabulas R. M., Ahmad-Nejad P., da Costa C. et al. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells // J. Biol. Chem. 2001. Vol. 276. P. 31332–31339.
33. Edfeldt K., Swedenborg J., Hansson G. K. et al. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation // Circulation. 2002. Vol. 105. P. 1158–1161.
34. Xu X. H., Shah P. K., Faure E. et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL // Circulation. 2001. Vol. 104. P. 3103–3108.
35. Лиходед В. Г. Экзогенные и эндогенные факторы в патогенезе атеросклероза. Рецепторная теория атерогенеза / В. Г. Лиходед, В. М. Бондаренко, А. Л. Гинцбург // Рос. кардиол. журн. – 2010. – Т. 82, № 2. – С. 92–96.
36. Ashida K., Miyazaki K., Takayama E. at al. Characterization of the expression of TLR2 (toll-like receptor 2) and TLR4 on circulating monocytes in coronary artery disease // J. Atheroscler. Thromb. 2005. Vol. 12. P. 53–60.
37. Versteeg D., Hoefer I. E., Schoneveld A. H. et al. Monocyte Toll-like receptor 2 and 4 responses and expression following percutaneous coronary intervention: association with lesion stenosis and fractional flow reserve // Heart. 2008. Vol. 94. P. 770 –776.
38. Rittersma S. Z. H., Hovinga J. A. K., Koch K. T. et al. Relationship between in vitro lipopolysaccharide-induced cytokine response in whole blood, angiographic in-stent restenosis, and Toll-Receptor 4 gene polymorphisms // Clin. Chem. 2005. Vol. 51, N 3. P. 516–521.
39. Mullick A. E., Soldau K., Kiosses W. B. et al. Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events // J. Exp. Med. 2008. Vol. 205. P. 373–383.
40. Brunn G. J., Bungum M. K., Johnson G. B., Platt J. L. Conditional signaling by Toll-like receptor 4 // FASEB J. 2005. Vol. 19. P. 872–874.
41. Rifkin I. R., Leadbetter E. A., Busconi L. at al. Toll-like receptors, endogenous ligands, and systemic autoimmune disease // Immunol. Rev. 2005. Vol. 204. P. 27–42.
42. Ishikawa Y., Satoh M., Itoh T. et al. Local expression of Toll-like receptor 4 at the site of ruptured plaques in patients with acute myocardial infarction // Clin. Sci. (Lond). 2008. Vol. 115. P. 133–140.
43. Methe H., Kim J. O., Kofler S. et al. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes // Arterioscler. Thromb. Vasc. Biol. 2005. Vol. 25. P. 1439–1445.
44. Tavener S. A., Long E. M., Robbins S. M. et al. Immune cell Toll-like receptor 4 is required for cardiac myocyte impairment during endotoxemia // Circ. Res. 2004. Vol. 95. P. 700–707.
45. Bjorkbacka H., Kunjathoor V.V., Moore K.J. et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways // Nat. Med. 2004. Vol. 10. P. 416–421.
46. O’Neill L. A., Bowie A. G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signaling // Nat. Rev. Immunol. 2007. Vol. 7. P. 353–364.
47. Monaco C., Gregan S. M., Navin T. J. et al. Toll-like receptor-2 mediates inflammation and matrix degradation in human // Circulation. 2009. Vol. 120. P. 2462–2469.
48. Misch E. A., Hawn T. R. Toll-like receptor polymorphisms and susceptibility to human disease // Clin. Sci. 2008. Vol. 114. P. 347–360.
49. Ferwerda B., McCall M. B., Alonso S. et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans // Proc. Nat. Acad. Sci. 2007. Vol. 104. P. 16645–16650.
50. Schmitt C., Humeny A., Becker C. M. et al. Polymorphisms of TLR4: Rapid genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles // Clin. Chem. 2002. Vol. 48. P. 1661–1667.
51. Ioana M., Ferwerda B., Plantinga T. S. et al. Different patterns of Toll-like receptor 2 polymorphisms in populations of various ethnic and geographic origins // Infect. Immun. 2012. Vol. 80, N 5. P. 1917–1922.
52. Lorenz E., Mira J. P., Cornish K. L. et al. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection // Infect. Immun. 2000. Vol. 68. P. 6398–6401.
53. Texereau J., Chiche J., Taylor W. et al. The importance of Toll-Like receptor 2 polymorphisms in severe infections // Clin. Infect. Dis. 2005. Vol. 41. P. 408–415.
54. Скочко О. В. Значение полиморфизма Asp299Gly Toll-подобного рецептора 4 в патогенезе атеросклероза / О. В. Скочко // Актуальні проблеми сучасної медицини. – 2013. – Т. 2, № 42. – С. 229–232.
55. Hamann L., Gomma A., Schroder N. W. et al. A frequent Toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis // J. Mol. Med. 2005. Vol. 83. P. 478–485.
56. Labrum R., Bevan S., Sitzer M. et al. Toll Receptor polymorphisms and carotid artery intima-media thickness // Stroke. 2007. Vol. 38. P. 1179–1184.
57. Arbour N. C., Lorenz E., Schutte B. C. et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans // Nat. Genet. 2000. Vol. 25. P. 187–191.
58. Kiechl S., Lorenz E., Reindl M. et al. Toll-like receptor 4 polymorphisms and atherogenesis // N. Engl. J. Med. 2002. Vol. 347. P. 185–192.
59. Ameziane N., Beillat T., Verpillat P. et al. Association of the toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events // Arterioscler. Thromb. Vasc. Biol. 2003. Vol. 23. P. e61–e64.
60. Boekholdt S. M., Agema W. R., Peters R. J. et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events // Circulation. 2003. Vol. 107. P. 2416–2421.
61. Yang I. A., Holloway J. W., Ye S. TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis // Atherosclerosis. 2003. Vol. 170. P. 187–190.
62. Von Aulock S., Schroder N. W., Gueinzius K. et al. Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood // J. Infect. Dis. 2003. Vol. 188. P. 938–943.
63. Erridge C., Stewart J., Poxton I. R. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signaling // J. Exp. Med. 2003. Vol. 197. P. 1787–1791.
64. Edfeldt K., Bennet A. M., Eriksson P. et al. Association of hyporesponsive toll-like receptor 4 variants with risk of myocardial infarction // Eur. Heart J. 2004. Vol. 25. P. 1447–1453.
65. Kuivenhoven J. A., Jukema J. W., Zwinderman A. H. et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis // N. Engl. J. Med. 1998. Vol. 338. P. 86–93.
66. Radstake T. R., Franke B., Hanssen S. et al. The Toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome // Arthr. Rheum. 2004. Vol. 50. P. 999–1001.
67. Menghini R., Campia U., Tesauro M. et al. Toll-like receptor 4 mediates endothelial cell activation through NF-kB but is not associated with endothelial dysfunction in patients with rheumatoid arthritis // PLoS ONE. 2014. Vol. 9, N 6. P. e99053.
68. Netea M. G., Hijmans A., van Wissen S. et al. Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolemia // Eur. J. Clin. Invest. 2004. Vol. 34. P. 94–99.
69. Zhang K., Zhang L., Zhou B. et al. Lack of association between TLR4 Asp299Gly polymorphism and atherosclerosis: evidence from meta-analysis // Thromb. Res. 2012. Vol. 130. P. e203–e208.
70. Koch W., Hoppmann P., Pfeufer A. et al. Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population // Eur. Heart J. 2006. Vol. 27. P. 2524–2529.